European Archives - Page 639 of 1561 - European Medical Journal

ACG Updates Guidelines for Management of Helicobacter Pylori

The American College of Gastroenterology (ACG) has issued a new clinical guideline to help healthcare providers more effectively manage Helicobacter pylori….

Clear Skin Ahead: Upadacitinib Shows Promise for Teens Battling Atopic Dermatitis

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to improve management of this chronic condition.

ER+/HER2- Metastatic Breast Cancer – Treatment after ET + CDK4/6i

Menarini Stemline’s key symposium from the 2024 European Society for Medical Oncology (ESMO) Congress, focused on treatment strategies…

31 Oct 2024

Under the Lens: Progression of Diabetic Retinopathy and the Impact of Fenofibrate

With an increasing prevalence of diabetic retinopathy, a cause of vision impairment and blindness in those with diabetes, there is a need…

AML Expert-Led Webinar: Exploring Maintenance Approaches in AML

Watch Part 2 of the Expert Webinar series on acute myeloid leukaemia (AML) maintenance therapy (catch up on Part 1 of the…

Spoonful of Technology: Sept-Oct

Take a look at the latest examples of how pharma and its partners are working together to develop technology to solve key challenges.

Coins falling

ABPI welcomes the UK Chancellor’s new Budget

The Association of the British Pharmaceutical Industry has expressed support for the first Labour budget in 14 years.

Potential Survival Benefits of Transplant for TP53-Mutated Acute Myeloid Leukemia

A recent multicenter study led by researchers including Talha Badar and Moazzam Shahzad has highlighted the challenging prognosis of TP53-mutated acute myeloid leukemia.

MRI Screening Reduces Unnecessary Biopsies in Prostate Cancer

Prostate cancer remains a significant health concern for men, particularly those aged between 50 and 60 years.

Asthma Drug Does Not Reduce COVID-19 Symptom Duration

A NEW clinical trial has found that the asthma drug montelukast does not shorten the duration of symptoms for mild-to-moderate COVID-19 patients compared to a placebo.